The State of Asthma in America Right Now
The numbers paint a sobering picture. According to the Centers for Disease Control and Prevention, roughly 8.4% of the US population currently lives with asthma, translating to about 27.8 million people. Among them, 4.8 million are children under 18. The condition does not distribute itself evenly. Women, Black Americans, and households with lower incomes bear a disproportionate share of the burden, and the prevalence has been climbing steadily over the past two decades. A recent analysis of national health data spanning 1999 to 2023 found that current asthma rates rose from 6.5% to 9.3% during that period.
What makes these statistics particularly relevant to clinical research is that while emergency department visits and asthma attacks have declined, many patients still struggle to achieve consistent control. Standard therapies like inhaled corticosteroids and long-acting beta agonists work well for a large portion of the population, but a significant minority continues to experience flare-ups, nighttime awakenings, and limitations on daily activities. This gap between available treatments and real-world outcomes is exactly where asthma clinical trials come in. Researchers across the country are testing new biologics, combination inhalers, and even lifestyle interventions designed to close that gap.
One recent development worth noting is the approval of Breztri Aerosphere for asthma maintenance in patients aged 12 and older, based on two Phase III studies called KALOS and LOGOS. The triple-combination inhaler was already used for COPD, and its expansion into asthma reflects how research continues to reshape treatment options. Another example is EXDENSUR, a long-acting injectable for severe eosinophilic asthma that received regulatory clearance in late 2025 and is administered just once every six months. These breakthroughs did not materialize overnight. Each one depended on thousands of volunteers who enrolled in asthma research studies across the country.
What Happens Inside an Asthma Clinical Trial
Clinical trials follow a structured path, and knowing the phases helps demystify the process. Phase I studies typically involve a small group of healthy volunteers or patients and focus on safety and dosage. Phase II expands to a few dozen or a few hundred participants to gauge effectiveness and side effects. Phase III trials, like the KALOS and LOGOS studies mentioned earlier, involve hundreds or thousands of patients across multiple sites and are designed to confirm a treatment works before it goes to regulators. Phase IV studies happen after approval, monitoring long-term effects in the general population.
Most people who search for asthma clinical trials for adults or pediatric asthma clinical trials will encounter Phase II or III studies. These trials usually compare an investigational treatment against either a placebo or an existing standard therapy. Participants are randomly assigned to one group or the other, and in many cases neither the patient nor the doctor knows which group they are in until the study concludes. This double-blind design reduces bias, but it also means you might receive a placebo instead of the experimental drug. That uncertainty is one of the first things to weigh carefully before enrolling.
The commitment varies widely. Some trials require weekly visits to a research center for lung function tests, blood draws, and questionnaires. Others involve a handful of check-ins spread over several months. Duke University's Asthma, Allergy and Airway Center, for instance, runs multiple active trials including the CHRONICLE Study, a long-term observational registry for severe asthma, and the PREPARE study, which examines whether using an inhaled corticosteroid alongside a rescue inhaler reduces hospitalizations. The PREPARE study offers compensation for participation, which brings up a practical question many people have.
Compensation and Costs: What to Expect
Financial considerations matter, and the landscape is not uniform. Some trials reimburse participants for time and travel, while others provide the investigational treatment and related medical care at no charge. The Asthma and Allergy Clinical Research Center at Boston Children's Hospital, for example, states that compensation can reach up to $2,540 depending on the study, with additional reimbursements for parking and transportation. Other sites may offer different arrangements, and the amount often reflects the intensity of the study protocol.
It is important to understand that asthma clinical trials compensation is not a salary. It is meant to offset inconvenience and expenses, and the amounts are reviewed by institutional review boards to ensure they are reasonable rather than coercive. If a trial requires overnight stays, frequent blood draws, or invasive procedures like bronchoscopies, the compensation tends to be higher. Observational studies that involve little more than periodic surveys and lung function tests generally offer less.
Costs to participants are typically minimal. The investigational drug, study-related lab work, and visits to the research team are usually covered by the sponsor. Routine care, such as your existing asthma medications and visits to your regular doctor, remains your responsibility. Some trials work with your insurance for certain procedures, but many do not bill insurance at all. Asking the study coordinator for a clear breakdown of what is covered and what is not should be one of your first steps before signing any consent forms.
| Study Type | Typical Duration | Compensation Range | Ideal For | Key Consideration |
|---|
| Phase II interventional | 3 to 12 months | Modest, often $500-$1,500 | Patients not responding to standard therapy | Risk of placebo assignment |
| Phase III interventional | 6 months to 2 years | Varies, may reach $2,500+ | Broad asthma populations | More study visits required |
| Observational/registry | 1 to 5 years | Minimal, often $50-$200 per visit | Patients wanting to contribute data | No experimental treatment given |
| Biologic drug trials | 6 to 24 months | Moderate to high | Severe or eosinophilic asthma | May require injection training |
| Pediatric studies | 3 to 12 months | Often includes gift cards | Children with persistent symptoms | Parental consent and child assent needed |
Who Can Participate and What to Watch For
Eligibility criteria differ from study to study, but a few patterns emerge across most severe asthma clinical trials. Researchers typically require a confirmed asthma diagnosis of at least one year, and participants must be on a stable medication regimen for a defined period before enrollment. Lung function tests, particularly the forced expiratory volume in one second, often need to fall below a certain threshold. For trials targeting eosinophilic asthma, blood eosinophil counts become a key screening metric. Age restrictions vary, with some studies enrolling patients as young as 12 and others focusing exclusively on adults.
Maria, a 34-year-old teacher in Houston, spent years cycling through inhalers that helped only partially. Her pulmonologist mentioned a Phase II trial for a biologic targeting interleukin-33, a molecule involved in the inflammatory cascade. She qualified because her eosinophil count was elevated and her symptoms persisted despite high-dose inhaled corticosteroids. The trial required monthly injections and quarterly clinic visits. After six months, her nighttime awakenings dropped from four times a week to almost none. She acknowledges that not everyone gets the same result, and the possibility of receiving a placebo was real, but for her the experience opened a door that standard care had left closed.
Side effects are another crucial piece of the puzzle. Investigational treatments carry unknown risks, which is the entire point of studying them. Common side effects in asthma trials include injection site reactions, headaches, and upper respiratory infections. More serious adverse events, though rare, can occur. The informed consent document will outline every known risk, and the research team is required to review it with you in detail. Reading it thoroughly and asking questions about anything unclear is not optional. It is the foundation of your decision.
Finding a Trial Near You
The search for asthma clinical trials near me starts with a few reliable resources. ClinicalTrials.gov, maintained by the National Library of Medicine, is the largest database and allows filtering by condition, location, phase, and recruitment status. Major academic medical centers, including Duke, Boston Children's Hospital, and the University of California system, maintain their own listings of active studies. The American Lung Association and the Allergy and Asthma Network also provide directories and educational materials.
Once you identify a potential trial, the next step is reaching out to the study coordinator. Prepare a list of your current medications, your asthma history, and any questions about time commitment, risks, and compensation. The coordinator will likely conduct a phone screening to determine whether you meet the basic criteria before scheduling an in-person visit. That first visit often includes a detailed explanation of the study, a physical exam, and baseline lung function testing.
Bringing a family member or friend to the screening visit can help you process the information. The volume of details can feel overwhelming, and a second set of ears often catches things you might miss. Some people also find it helpful to ask the coordinator to connect them with a former participant willing to share their experience. Not every site offers this, but it does not hurt to ask.
For those with severe or difficult-to-control asthma, biologic asthma clinical trials represent a particularly active area of research. Drugs targeting specific inflammatory pathways continue to enter the pipeline, and many of these studies are designed as add-on therapies, meaning participants continue their existing medications while receiving the investigational treatment. This design can reduce some of the anxiety around the possibility of receiving a placebo alone, since standard care remains in place regardless of group assignment.
The decision to join a clinical trial is personal and layered. It involves weighing the possibility of accessing a new treatment against the uncertainty of unproven safety profiles. It means committing time and energy to study visits while potentially contributing to science that helps millions of others. The asthma research landscape in the United States is active and diverse, with studies ranging from brief observational registries to multi-year interventional trials. If your current treatment plan leaves you short of breath more often than it should, talking to your doctor about research options might be a conversation worth having.
研究の知恵